Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rhythm Pharmaceuticals reports robust Q4 performance and eyes growth

Rhythm Pharmaceuticals had a strong performance in Q4 2022, driven by increased IMCIVREE sales and strategic pipeline expansions.
While facing challenges in logistics and reimbursement, the company's strengths lie in its geographic expansion, pipeline diversification, and patient-focused approach.
Opportunities for growth include upcoming launches, patient identification efforts, and maximizing the potential of the BBS commercial opportunity.

Rhythm Pharmaceuticals excels in Q1 with IMCIVREE revenue surge

Rhythm Pharmaceuticals demonstrated strong financial performance and market acceptance of IMCIVREE, supported by robust revenue growth and cash reserves.
While facing challenges in pricing negotiations and patient transitions, the company is well-positioned to capitalize on opportunities for further growth and development.
The identification of key genes in the DAYBREAK trial and positive patient feedback highlight the company's commitment to innovation and patient-centric care.
Overall, Rhythm Pharmaceuticals' Q1 earnings call showcases a promising outlook with solid performance, strategic strengths, addressable challenges, and growth opportunities.

Rhythm Pharmaceuticals excels in Q2, eyes international growth opportunities

Rhythm Pharmaceuticals delivered a strong Q2 performance with notable achievements in commercial execution and clinical development. Despite challenges in market ramp-up and reimbursement delays, the company remains well-capitalized and focused on strategic priorities. Opportunities for growth through international expansion and new drug formulations position Rhythm for continued success.

Rhythm Pharmaceuticals excels in Q3, faces discontinuation challenges

Rhythm Pharmaceuticals is making significant progress in commercial expansion and clinical trials, supported by strong financial position. Challenges include administrative hurdles and managing discontinuation rates. Opportunities exist in expanding prescriber base, educating specialties, and advancing clinical trials for younger patients.

Rhythm Pharmaceuticals surpasses revenue expectations, eyes international expansion and patient-centric innovation

Rhythm Pharmaceuticals delivered strong financial performance, highlighted by solid commercial execution and international market successes, despite challenges with Medicaid coverage.
The company's focus on innovation, unique value propositions, and upcoming milestone achievements position it for continued growth and market leadership.
Addressing discontinuation rates, Medicaid issues, and maximizing opportunities in international markets are key priorities for Rhythm Pharmaceuticals to drive sustained success.

Rhythm Pharmaceuticals reports strong Q1 performance and international growth

Rhythm Pharmaceuticals' Q1 performance reflects strong commercial traction, international growth, and strategic advancements in clinical programs.
While facing challenges like Medicaid changes and discontinuations, the company's proactive measures and focus on patient care position it well for growth.
Opportunities in new markets, patient populations, and improved retention strategies offer avenues for future expansion and revenue growth.
Overall, Rhythm Pharmaceuticals' earnings call highlights a balanced outlook with a focus on innovation, patient support, and international expansion.

Rhythm Pharmaceuticals reports robust Q2 revenues, eyes European growth

Rhythm Pharmaceuticals demonstrated solid revenue performance in Q2 2024 driven by IMCIVREE sales
The company maintains a strong cash position and is progressing well with its pipeline development
Challenges include managing expenses to ensure profitability and sustaining operations until 2026
Opportunities lie in product expansion, successful trial outcomes, and operational optimization

Rhythm Pharmaceuticals excels in Q3 with revenue growth and clinical progress

Rhythm Pharmaceuticals demonstrated strong performance in Q3 2024 with revenue growth and positive clinical trial outcomes.
The company's focus on expansion, engagement, and milestone achievements positions it well for future growth and market penetration.
While facing challenges in managing expenses and addressing analyst inquiries, Rhythm Pharmaceuticals has opportunities for international expansion and therapeutic advancements.
Overall, Rhythm Pharmaceuticals' strategic approach and financial stability indicate a promising outlook for continued success and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

ACADIA Pharma

Axsome Therapeutics

bluebird bio

Bristol-Myers

Moderna

Biotech investors stand to make a windfall if they make calculated bets by thoroughly researching on key catalysts that could move the stocks in a big way. The post 6 Biotech Stocks to Buy Now Ahead of These June Catalysts appeared first on InvestorPlace.

6 Biotech Stocks to Buy Now Ahead of These June Catalysts

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 5:20 p.m. PT (8:20 p.m. ET) in Las Vegas, NV.

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Healthcare Conference

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants David Connolly - Investor Relations and Corporate Communications David Meeker - Chair, President and Chief Executive Officer Jennifer Chien - Executive Vice President, Head of North America Linda Shapiro - Chief Medical Officer Hunter Smith - Chief Financial Officer Yann Mazabraud - Executive Vice President, Head of International Conference Call Participants Derek Archila - Wells Fargo Joseph Stringer - Needham & Company Michael Higgins - Ladenburg Thalmann Jeff hung - Morgan Stanley Corinne Jenkins - Goldman Sachs Operator Welcome to the Rhythm Pharmaceuticals First Quarter 2022 Earnings Conference Call. My name is Hilda and I'll be your operator today's call.

Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q1 2022 Results - Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -7.14% and 38.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

-- Patient identification and physician engagement ongoing in preparation for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial patients treated with IMCIVREE ® (setmelanotide) in France under paid early access program --

Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update

BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 3, 2022 to report its first quarter 2022 financial results and provide a corporate update.

Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

Rhythm Pharmaceuticals, Inc. (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy?

Rhythm Pharmaceuticals (RYTM) modifies the design of its two genetic obesity disorder studies to focus on rare patients, thus reducing the targeted population size. RYTM expects to save costs in the process.

Rhythm Pharmaceuticals (RYTM) Down Due to Study Design Changes

Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) will modify its Phase 3 EMANATE and ongoing Phase 2 DAYBREAK trials of setmelanotide in rare genetic diseases of obesity Recent FDA feedback indicated that additional clinical trials to support potential registration for non-rare patient.

Rhythm Pharma Shares Fall After Modifications To Setmelanotide Trials In Rare Diseases of Obesity

– Phase 3 EMANATE trial to focus on rare patient populations with highest likelihood for success –

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

NEW YORK , March 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Rhythm Pharmaceuticals, Inc. ("Rhythm" or the "Company") (NASDAQ: RYTM).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rhythm Pharmaceuticals, Inc. - RYTM

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Wren Appoints Bart Henderson as Chief Executive Officer

Wren Appoints Bart Henderson as Chief Executive Officer

Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q4 2021 Results - Earnings Call Transcript

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the Cowen & Co. 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 10:30 a.m. ET.

Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference

-- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 –

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced the promotions of Joe Shulman to Chief Technical Officer, Patrick Kleyn, Ph.D., to Senior Vice President and Head of Translational Research and Development, and Elisabeth Crönert-Bendell, M.D., to Senior Vice President and Head of Strategy.

Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, March 1, 2022 to report its fourth quarter and full year 2021 financial results and provide a corporate update.

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022

Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) has announced interim data from its long-term extension study evaluating setmelanotide in patients with Bardet-Biedl Syndrome (BBS). BBS is a genetic disorder characterized by rod/cone dystrophy, polydactyly, central obesity, hypogonadism, and kidney dysfunction in some cases.

Rhythm Pharma's Highlights Interim Setmelanotide Data In Long Term Genetic Disorder Trial

-- Key opinion leaders and patient caregiver to discuss patient experience -- -- Company to provide update on U.S. BBS commercial readiness during event for investors and analysts --

Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16

RYTM has a label expansion for its lead molecule. The molecule is approved in another indication for over a year.

Rhythm Pharmaceuticals: PDUFA Ahead, But Commercialization Concerns Remain

-- DAYBREAK is the most comprehensive Phase 2 trial ever initiated in rare genetic diseases of obesity -- -- DAYBREAK is evaluating setmelanotide in patients with severe obesity and hyperphagia caused by variants in one of 31 pre-identified genes -- -- First patient also dosed in Phase 3 switch trial evaluating a weekly formulation of setmelanotide -- BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced the first patient has been dosed with setmelanotide, the company's melanocortin-4 receptor (MC4R) agonist, in the Phase 2 DAYBREAK clinical trial to treat the severe obesity and hyperphagia potentially caused by a genetic variant that impairs function of the MC4R pathway. The company also announced the dosing of the first patient in the Phase 3 trial evaluating a switch from the daily to a novel weekly formulation of setmelanotide.

Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity

-- RareStone to seek marketing authorization for IMCIVREE to treat obesity due to biallelic POMC, PCSK1 and LEPR deficiencies and Bardet-Biedl and Alström syndromes in mainland China, Hong Kong and Macau ---- Rhythm to receive $12 million upfront in cash and equity, up to $63.5 million in future milestone payments and sales royalties -- BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, and RareStone LTD, formerly Citrine Medicine, a China-based rare disease company, today announced an exclusive licensing agreement for the development and commercialization of IMCIVREE® (setmelanotide) in China, including mainland China, Hong Kong and Macau. This licensing agreement marks the first expansion of Rhythm's pipeline into Asia and is designed to accelerate patient access to IMCIVREE where there remains significant unmet need to address the severe, early-onset obesity and hyperphagia that characterize both acquired and genetic diseases of the melanocortin-4 receptor (MC4R) pathway.

Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China

FDA sets PDUFA goal date of March 16, 2022 FDA sets PDUFA goal date of March 16, 2022

Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q3 2021 Results - Earnings Call Transcript

-- U.S. and EU regulatory filings submitted for IMCIVREE ® (setmelanotide) for treatment of Bardet-Biedl and Alström syndromes; launch preparations underway -- -- Delivered a total of 22 presentations at three major medical conferences -- -- New presentations include first-ever data showing improvements in health-related quality of life in rare genetic diseases of obesity -- -- IMCIVREE third quarter net sales reach $1M -- -- Management to Host Conference Call at 8:00 a.m. ET -- BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today reported financial results and provided a business update for the third quarter ended September 30, 2021.

News for Rhythm Pharmaceuticals Stock (RYTM)